Evotec AG: New Hormone to Treat Diabetes Published in "Cell"

Evotec AG: New Hormone to Treat Diabetes Published in "Cell"

Harvard University Prof. Doug Melton and His Post Doc Peng Yi Describe the New
Hormone "Betatrophin" That Controls Beta Cell Proliferation as Potential
Diabetes Treatment

HAMBURG, Germany, April 26, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) (ISIN:DE0005664809) today announced an auspicious step in research
from Harvard University. The findings are published in a scientific article by
Prof. Doug Melton, University professor at Harvard University and Howard
Hughes Medical Institute (HHMI) investigator and his post doc Peng Yi in the
journal Cell. Doug Melton is the academic key collaborator of CureBeta, a
strategic alliance between Harvard University, Evotec and Janssen
Pharmaceuticals in the field of beta cell regeneration.

In the article, available as of 25 April 2013 in the online edition of Cell,
Doug Melton, who is also the co-director of the Harvard Stem Cell Institute
and his post doc Peng Yi release the discovery of the new hormone betatrophin
that controls beta cell proliferation. All intellectual property associated
with these findings have been licensed to Evotec in March 2011 and
subsequently sublicensed to Janssen Pharmaceuticals within the CureBeta
collaboration announced in July 2012.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Restoring
beta cell mass and function is the most promising approach to slow down or
reverse disease progression in diabetic patients. The laboratory of Doug
Melton has made a series of important contributions to this beta field in
particular demonstrating that beta cell proliferation is a key mechanism that
controls beta cell mass. His latest publication describes a previously
underappreciated capacity of beta cells to proliferate in response to a
pharmacological trigger and the identification of a novel physiological
mediator, betatrophin."

ABOUT CUREBETA

In the beginning of 2011, Evotec, Harvard and the Howard Hughes Medical
Institute (HHMI) established the CureBeta initiative. The initial goal of the
collaboration was to pursue a comprehensive and systematic approach towards
the identification and development of physiological mechanisms and targets
that regulate beta cell replication. During the initial period of the
collaboration, Evotec, HHMI and Harvard established new standards in beta cell
regeneration in terms of assays and tools as well as novel high potential
targets. In July 2012, Janssen Pharmaceuticals entered into this
collaboration. Janssen received exclusive access to a series of candidates
designed to trigger the regeneration of insulin-producing beta cells. The
small molecules and biologics were identified by scientists in the Harvard
University laboratory of Douglas Melton and further analysed in collaboration
with scientists from Evotec, as part of the CureBeta research and development
programme.

ABOUT DIABETES

Diabetes Mellitus is a chronic incapacitating disease associated with severe
life-long conditions such as cardiovascular diseases, kidney diseases, nerve
damage and eye diseases, which require intensive monitoring and control.
Diabetes is caused by relative or complete decrease in insulin production and
secretion by pancreatic beta cells. Furthermore, diabetes can be caused by the
reduced effectiveness of secreted insulin in consequence of the gradual loss
of insulin sensitivity of target cells which is called insulin resistance. At
present, there is no cure for diabetes and only symptomatic treatment options
are available. The most common diabetes types are type 1 and type 2 diabetes.
Currently, about 90-95% of diabetes patients worldwide have type 2 diabetes.
According to the International Diabetes Foundation, there are 371 million
people worldwide who are diagnosed with diabetes (2011: 366 million) and about
187 million who are at risk of costly and debilitating diabetes complications
who have not yet been diagnosed. It is estimated that about 4.8 million people
will have died from diabetes at the end of 2012 (2011: 4.0 million).
Concerning the diabetes market volume, approx. $471 bn were spent on the
treatment of diabetes in 2012 (2011: $465 bn).

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Dr. Werner Lanthaler
         Chief Executive Officer
         +49.(0)40.560 81-242
         +49.(0)40.560 81-333 Fax
         werner.lanthaler@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)
        
         Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         gabriele.hansen@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)
 
Press spacebar to pause and continue. Press esc to stop.